<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Childhood lead poisoning: Clinical manifestations and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Childhood lead poisoning: Clinical manifestations and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Childhood lead poisoning: Clinical manifestations and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer A Sample, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michele M Burns, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jan E Drutz, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James F Wiley, II, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 19, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical manifestations and diagnosis of lead toxicity will be reviewed here.
        </p>
        <p>
         Prevention and treatment of lead poisoning are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6493.html" rel="external">
          "Childhood lead poisoning: Exposure and prevention"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6494.html" rel="external">
          "Childhood lead poisoning: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lead (Pb), a stable metallic element with an atomic number of 82 and atomic weight of 207, was first smelted around 4000 BC as a byproduct of silver processing [
         <a href="#rid1">
          1
         </a>
         ]. The consequences of lead toxicity have been recognized for millennia [
         <a href="#rid2">
          2
         </a>
         ]. Despite this knowledge, lead was included as an ingredient of gasoline in the 1920s and continued to be used in paint in some developed countries until the 1970s [
         <a href="#rid3">
          3,4
         </a>
         ]. In many low-income countries, lead in gasoline and industrialized uses of lead (eg, smelters, mines, or refineries) remain major sources of exposure [
         <a href="#rid1">
          1
         </a>
         ]. About 50 percent of the worldwide burden of lead poisoning occurs in Southeast Asia [
         <a href="#rid5">
          5
         </a>
         ]. In 2021, UNICEF estimated that one in three children, globally, had blood lead levels (BLLs) &gt;5 mcg/dL (0.24 micromol/L) [
         <a href="#rid1">
          1,6
         </a>
         ].
        </p>
        <p>
         Risk factors, sources, and prevention of childhood lead poisoning include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – Children younger than six years of age (and particularly those younger than 36 months) are more susceptible to the toxic effects of lead than are adults because they have an incomplete blood-brain barrier that permits the entry of lead into the developing nervous system, and because they have a greater prevalence of iron deficiency, which can result from and cause lead poisoning through increased absorption of lead from the gastrointestinal tract [
         <a href="#rid7">
          7-9
         </a>
         ]. In addition, they are at greater risk of exposure to lead dust because of crawling, higher respiratory rates, and hand-to-mouth behavior.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The prevalence of elevated BLLs is highest among urban children who live in deteriorating housing that was built before the 1970s, and children exposed to lead as a result of industrialized use (eg, aerosolized lead from smelters or refineries or lead in water near mining operations) [
         <a href="#rid1">
          1,10,11
         </a>
         ]. Lead poisoning is more common among urban than rural children, low-income than middle-income children, and children who live in older housing [
         <a href="#rid11">
          11-16
         </a>
         ]. While the prevalence of elevated BLLs has decreased over time, disparities in the geometric mean of BLLs continue when assessing for ethnicity and income level. In the United States, Black children continue to have a statistically higher BLL compared with other populations. In addition, the prevalence of lead poisoning is increased among refugee children who have arrived recently in the United States, and among children entering foster care [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sources
         </strong>
         – Children typically are exposed to environmental lead through ingestion or inhalation. Common sources include chips of paint or lead dust from lead-painted surfaces; food or beverages purchased, stored, or served in lead-soldered cans or lead-glazed pottery; water from lead-soldered plumbing; automobile emissions; and lead-using industry  (
         <a class="graphic graphic_table graphicRef53953" href="/z/d/graphic/53953.html" rel="external">
          table 1
         </a>
         ). Although the United States phased out lead-soldered food cans during the 1980s, imported canned goods may still contain lead [
         <a href="#rid10">
          10
         </a>
         ]. Less common sources of lead exposure include herbal and folk medications, imported crayons and other toys, mini blinds, cosmetics, jewelry, and imported cookware [
         <a href="#rid10">
          10,16,19
         </a>
         ]. Parental take-home exposures may also result in elevated BLLs in children [
         <a href="#rid20">
          20
         </a>
         ]. Adolescents may have an increased risk due to hobbies and occupational exposures in firing ranges and lead dust that accumulates in these facilities [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6493.html" rel="external">
          "Childhood lead poisoning: Exposure and prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         – Removal of the common sources of lead exposure has resulted in declining BLLs in children. As an example, in the United States, as lead was removed from gasoline and paint, the average BLL in children decreased from 16 mcg/dL (0.77 micromol/L) to less than 3 mcg/dL (0.14 micromol/L) in 1991 [
         <a href="#rid12">
          12,22
         </a>
         ]. This trend in declining BLL in United States children less than five years of age has continued with the estimated geometric mean of 0.67 mcg/dL [
         <a href="#rid23">
          23,24
         </a>
         ] in 2018 [
         <a href="#rid25">
          25
         </a>
         ]. Residual lead from these and other products remains in the environment because elemental lead cannot be degraded. In many resource-limited parts of the world, lead continues to be used in gasoline, pigment (eg, in paint, cosmetics, and crayons), pottery glaze, solder, cooking vessels, jewelry, toys, and even medications [
         <a href="#rid5">
          5
         </a>
         ]. These products occasionally are imported into the United States and are potential sources of lead exposure. Although the incidence and severity of lead poisoning in the United States are decreasing, an estimated 450,000 children in the United States were above the reference value of 3.5 mcg/dL (0.14 micromol/L) in 2021 [
         <a href="#rid26">
          26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6493.html" rel="external">
          "Childhood lead poisoning: Exposure and prevention", section on 'Prevention'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          TOXICOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The key aspects determining toxicity are based upon blood lead levels (BLLs), the disposition of lead once it enters the body (toxicokinetics), and molecular toxicology as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxic level
         </strong>
         – The American Academy of Pediatrics and the Centers for Disease Control and Prevention (CDC) state that no safe or "nontoxic" BLL exists. In the United States, a reference level corresponding to the 97.5
         <sup>
          th
         </sup>
         percentile of BLLs in children in the United States (3.5 mcg/dL [0.14 micromol/L] as of 2021) has been adopted [
         <a href="#rid26">
          26
         </a>
         ]. The reference level should not be mistaken for an "action" level as this terminology has changed based on the science that has shown lead to be more toxic than previously thought. Between 1970 and 2012, the toxic level or "action" level was gradually decreased from 60 mcg/dL (2.9 micromol/L) to 10 mcg/dL (0.48 micromol/L). In 2012, the CDC, recognizing that no safe blood level existed, established a reference level at the 97.5
         <sup>
          th
         </sup>
         percentile of BLLs in children in the United States (3.5 mcg/dL [0.14 micromol/L] as of 2021)  (
         <a class="graphic graphic_table graphicRef64183" href="/z/d/graphic/64183.html" rel="external">
          table 2
         </a>
         ). The decrease in 1991 was prompted by evidence of cognitive and behavioral effects of low-level lead toxicity [
         <a href="#rid27">
          27,28
         </a>
         ]. Changes in the definition of the toxic level have been accompanied by changes in policies for screening, treatment, and prevention [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2872.html" rel="external">
          "Screening tests in children and adolescents", section on 'Lead poisoning'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6494.html" rel="external">
          "Childhood lead poisoning: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicokinetics
         </strong>
         – Inorganic lead is not metabolized but is directly absorbed, distributed, and excreted. The absorption of lead depends upon the route of exposure and the age and nutritional status of the exposed individual [
         <a href="#rid10">
          10
         </a>
         ]. Inhaled lead may either be cleared by cilia, resulting in ingestion, or retained by the lung (30 to 50 percent) for rapid and complete absorption [
         <a href="#rid30">
          30
         </a>
         ]. Children absorb a greater proportion of lead from the gastrointestinal tract than do adults (up to 70 versus 20 percent) [
         <a href="#rid31">
          31,32
         </a>
         ]. Fasting, iron deficiency, and calcium deficiency also may increase the gastrointestinal absorption of lead [
         <a href="#rid10">
          10,33,34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Lead that is absorbed from the gastrointestinal or respiratory tracts is distributed by a three-compartment model to the blood, soft tissues, and bone (trabecular and cortical). The half-life of lead varies depending upon the body compartment and the age of the child [
         <a href="#rid10">
          10,30,35-38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         On average, the half-life in each compartment is:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Blood – 28 to 36 days
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Soft tissue – 40 days
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mineralizing tissues – Greater than 25 years
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Lead that is not retained in the tissues is excreted by the kidneys or through biliary clearance into the gastrointestinal tract. Children younger than two years of age retain approximately one-half of absorbed lead, whereas adults ultimately retain only 1 percent [
         <a href="#rid10">
          10
         </a>
         ]. More than 70 percent of the total body burden of lead in children is contained in the mineralized tissues [
         <a href="#rid10">
          10,39
         </a>
         ]. Thus, the BLL is not a good reflection of the total body lead burden. In general, the concentration of lead in other organs is comparable to that found in blood. Approximately 99 percent of the lead in blood is bound to red blood cells. The remaining 1 percent (ie, plasma lead) serves as an intermediate in transporting lead from the erythrocytes to other body compartments.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The lead in mineralizing tissues accumulates in two subcompartments: a labile compartment that readily exchanges lead with the blood, and an inert pool [
         <a href="#rid38">
          38
         </a>
         ]. The inert pool of lead can be mobilized during periods of physiologic stress (eg, pregnancy, lactation, fractures, chronic disease) and represents an endogenous source of lead that can maintain an elevated BLL long after the exogenous exposure source has been removed [
         <a href="#rid10">
          10
         </a>
         ]. Because the body accumulates lead over a lifetime and releases it slowly, lead toxicity may occur without a major acute exposure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Molecular toxicology
         </strong>
         – Lead is a potent toxic substance with no apparent threshold [
         <a href="#rid40">
          40
         </a>
         ]. Lead interferes with the interactions of divalent cations and sulfhydryl groups. It has widespread physiologic effects because most biochemical reactions are regulated by these agents [
         <a href="#rid41">
          41,42
         </a>
         ]. In vitro, many of the reactions in which lead serves as a competitive inhibitor are reversible. However, in vivo, downstream events lead to cell death and irreversible damage at the cellular level, particularly in the central nervous system [
         <a href="#rid43">
          43-45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Lead can disrupt signal transduction cascades by activating protein kinase C, competing with magnesium and inhibiting cyclic nucleotide hydrolysis by phosphodiesterases, or inhibiting function at the N-methyl-D-aspartate-type glutamate receptor [
         <a href="#rid46">
          46-49
         </a>
         ]. Lead also can uncouple mitochondrial oxidative phosphorylation in the central nervous system [
         <a href="#rid45">
          45,50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Magnetic resonance spectroscopy (MRS) in individuals with elevated BLLs demonstrates reduction in the N-acetylaspartate/creatine and phosphocreatine ratios in the frontal gray matter, suggesting that lead poisoning affects metabolism in the brain [
         <a href="#rid51">
          51,52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Lead competes with calcium for entry into synaptosomes [
         <a href="#rid53">
          53
         </a>
         ] and interacts with numerous receptor-activated and voltage-gated cation channels [
         <a href="#rid54">
          54,55
         </a>
         ]. In addition, lead increases the infidelity of DNA and RNA polymerase, leading to somatic and germline mutations [
         <a href="#rid56">
          56,57
         </a>
         ]. Lead-exposed rodents have an increased incidence of cancer [
         <a href="#rid58">
          58-63
         </a>
         ]. However, this association has not been found in humans [
         <a href="#rid64">
          64-66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hematologic complications of lead toxicity result from the ability of lead to directly inhibit delta-aminolevulinic acid dehydratase (ALAD), enzymes necessary for heme biosynthesis, and ferrochelatase, a mitochondrial sulfhydryl enzyme causing increased urinary delta-aminolevulinic acid (ALA), urinary coproporphyrin, and erythrocyte zinc protoporphyrin [
         <a href="#rid67">
          67-70
         </a>
         ]. The enzymatic blocks responsible are partial. While anemia may not be seen until blood lead concentrations are markedly elevated, the effect on hemoglobin synthesis occurs at lower levels [
         <a href="#rid10">
          10
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         ALA dehydratase is inhibited at very low BLLs with no threshold yet apparent.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Elevation of erythrocyte protoporphyrin occurs at levels of 30 mcg/dL (1.48 micromol/L).
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reduced hemoglobin synthesis is found in children at levels of 40 (1.93 micromol/L) and in adults at levels of 50 mcg/dL (2.41 micromol/L), respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The basophilic stippling of red cells is due to the presence of aggregated ribosomes, which may also include mitochondrial fragments. Conditions, such as lead poisoning, can result in altered ribosomes to have a higher propensity to aggregate. With staining, this appears as increased basophilic granulation  (
         <a class="graphic graphic_picture graphicRef71989" href="/z/d/graphic/71989.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lead affects at least three major organ systems (see
         <a class="local">
          'Toxicology'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Central and peripheral nervous systems
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heme biosynthetic pathway
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Renal system with injury to the renal and cardiovascular systems closely related
        </p>
        <p>
        </p>
        <p>
         In the child, the most serious symptoms are found in the central nervous system with subtle effects (eg, decreased intelligence quotient [IQ] and cognitive effects) occurring at lower levels and severe effects (eg, seizures, encephalopathy) occurring at higher levels. The majority of children with elevated blood lead concentrations will be asymptomatic from overt clinical manifestations of lead poisoning. Symptoms will vary depending upon the acuity of the lead exposure and the age of the exposed individual  (
         <a class="graphic graphic_table graphicRef76585" href="/z/d/graphic/76585.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         The clinical manifestations of lead poisoning in adults are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2773.html" rel="external">
          "Lead exposure, toxicity, and poisoning in adults", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Neurologic
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neurologic effects of lead poisoning in children include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurobehavioral deficits
         </strong>
         – Detectable blood lead levels (BLLs) are associated with neurocognitive deficits, and a lower limit for these effects has
         <strong>
          not
         </strong>
         been established in population studies. While blood lead tests may result below 5 mcg/dL (0.24 micromol/L), there is no safe lead level, and none should be considered "normal." Low-level lead poisoning may lead to permanent central nervous system injury in young children [
         <a href="#rid72">
          72
         </a>
         ]. Population-based studies consistently have shown that BLLs greater than 10 mcg/dL (0.48 micromol/L) affect the cognitive and behavioral development of children [
         <a href="#rid27">
          27,28,73-81
         </a>
         ]. However, neurocognitive effects also have been demonstrated at even lower BLLs, and no threshold is known to exist [
         <a href="#rid82">
          82-86
         </a>
         ]. Data suggests environmental lead exposure in children at blood lead concentrations &lt;7.5 mcg/dL (0.36 micromol/L) is associated with cognitive deficits. Furthermore, studies suggest that a permanent pattern of cognitive dysfunction may result from lead poisoning in the first several years of life [
         <a href="#rid87">
          87
         </a>
         ], and in-utero lead exposure may adversely affect infant neurodevelopment (measured at 24 months) independent of postnatal BLL [
         <a href="#rid88">
          88,89
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The neurobehavioral effects of lead poisoning appear to persist, at least in part, into adolescence and adulthood, despite a decline in BLL [
         <a href="#rid28">
          28,75,90-96
         </a>
         ]. As an example, in a longitudinal cohort study of over 1000 patients, lead exposure, based upon BLL at eleven years of age (mean BLL 11 mcg/dL [0.53 micromol/L]), was associated in a dose-dependent fashion with lower IQ and lower socioeconomic status at age 38 years despite adjustment for maternal IQ, child IQ, and childhood socioeconomic status [
         <a href="#rid97">
          97,98
         </a>
         ]. These studies are contradicted, however, by others that state the magnitude of these effects are small and cannot be interpreted at the individual child [
         <a href="#rid95">
          95,99,100
         </a>
         ]. Although studies cannot predict performance in an individual child with elevated BLL [
         <a href="#rid101">
          101
         </a>
         ], it is clear that primary prevention of lead exposures can prevent the adverse neurotoxic effects of lead.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, evidence also identifies other important variables besides elevated BLLs when assessing intelligence that may better explain the decline of intellectual abilities, such as parental and social environments [
         <a href="#rid95">
          95,100
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute encephalopathy
         </strong>
         – Acute encephalopathy occurs at BLLs greater than 100 to 150 mcg/dL (4.8 to 7.2 micromol/L) and is indicated by persistent vomiting, altered or fluctuating state of consciousness, ataxia, seizures, or coma. Cerebral edema is a variable finding, more often present in younger than older children. Children with lead encephalopathy may develop inappropriate antidiuretic hormone secretion [
         <a href="#rid102">
          102
         </a>
         ], partial heart block [
         <a href="#rid103">
          103
         </a>
         ], and marked decrease in renal function. (See
         <a class="local">
          'Renal'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hearing loss
         </strong>
         – The hearing loss occurs primarily in the higher frequencies and may contribute to learning and behavior problems [
         <a href="#rid10">
          10,104
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6297.html" rel="external">
          "Hearing loss in children: Screening and evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Peripheral neuropathy
         </strong>
         – Peripheral neuropathy, rare in children with isolated lead poisoning, is more common in children with concomitant sickle cell anemia [
         <a href="#rid105">
          105-108
         </a>
         ]. Decreased nerve conduction velocity occurs at BLLs as low as 20 mcg/dL (1 micromol/L) [
         <a href="#rid109">
          109,110
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Renal
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the child, lead appears to have an effect on renal function even at levels below 10 mcg/dL (0.48 micromol/L). This is especially true if the lead exposure occurs over a sustained period of time. Subtle abnormalities in renal tubular function, associated with aminoaciduria, glycosuria, and increased excretion of low-molecular weight proteins can occur [
         <a href="#rid111">
          111
         </a>
         ]. Lead nephropathy, which is characterized histologically by chronic interstitial nephritis, is a potential complication of prolonged high-level lead exposure. In addition, current levels of lead exposure have the potential for lead-related nephrotoxicity, primarily in adults with diabetes, hypertension, or underlying chronic kidney disease. These issues, including the long-term renal outcomes of childhood lead poisoning, are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7180.html" rel="external">
          "Lead nephropathy and lead-related nephrotoxicity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Gastrointestinal
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lead colic, which includes sporadic vomiting, intermittent abdominal pain, and constipation, may occur [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Endocrine
         </span>
         <span class="headingEndMark">
          —
         </span>
         BLLs and vitamin D levels are inversely related as lead interferes in the formation of active vitamin D, which has an important role in its influence on calcium metabolism. Calcium is under tight homeostatic control in all cells [
         <a href="#rid10">
          10,112
         </a>
         ]. Vitamin D metabolism is decreased at BLLs of 30 mcg/dL (1.45 micromol/L) [
         <a href="#rid112">
          112
         </a>
         ]. The effects of lead toxicity on cell growth and maturation and tooth and bone development probably are mediated through the effects on vitamin D [
         <a href="#rid10">
          10
         </a>
         ]. Likewise, because of the similar biochemical nature between lead and calcium, increased absorption of lead can occur, especially in children who have decreased calcium intake.
        </p>
        <p class="headingAnchor" id="H755017892">
         <span class="h2">
          Hematologic
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lead poisoning in children rarely results in anemia [
         <a href="#rid10">
          10
         </a>
         ]. The two major mechanisms are decreased hemoglobin synthesis and hemolysis. Decreased hemoglobin synthesis has been well documented at BLLs of 40 mcg/dL (1.9 micromol/L) [
         <a href="#rid113">
          113
         </a>
         ] and is caused by the interference of lead with several enzymatic steps in the heme pathway. With prolonged exposure to high levels of lead, red blood cell survival is diminished. Acute, high-level lead poisoning (BLL &gt;70 mcg/dL [3.4 micromol/L]) has been associated with hemolytic anemia [
         <a href="#rid10">
          10
         </a>
         ]. Increased erythrocyte destruction is more marked in adults than in children. Increased red cell fragility and decreased osmotic resistance may be observed. The degree of hemolysis is insufficient to produce jaundice. (See
         <a class="local">
          'Toxicology'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5927.html" rel="external">
          "Approach to the child with anemia"
         </a>
         .)
        </p>
        <p>
         Anemia in children with lead poisoning may in fact be caused by iron deficiency because lead poisoning and iron deficiency have similar risk factors [
         <a href="#rid114">
          114,115
         </a>
         ]. Anemia secondary to lead toxicity usually is mild, hemolytic, and normocytic. In contrast, anemia secondary to iron deficiency is hypochromic, microcytic, and reticulocytopenic [
         <a href="#rid116">
          116,117
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5925.html" rel="external">
          "Iron deficiency in infants and children &lt;12 years: Screening, prevention, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lead poisoning is diagnosed by an elevated venous blood lead level (BLL). Specific interventions for lead poisoning start at BLLs ≥3.5 mcg/dL (0.14 micromol/L), the current reference level as designated by the Centers for Disease Control and Prevention (CDC). (See
         <a class="local">
          'Lead levels'
         </a>
         below.)
        </p>
        <p>
         Specific treatment of childhood lead poisoning depends upon the degree of the blood lead elevation, the presence of symptoms, and local resources available for lead abatement. (See
         <a class="medical medical_review" href="/z/d/html/6494.html" rel="external">
          "Childhood lead poisoning: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Asymptomatic patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of lead toxicity usually is made through a lead screening program because most children with lead toxicity do not have overt clinical symptoms although neurobehavioral abnormalities may be present. (See
         <a class="medical medical_review" href="/z/d/html/2872.html" rel="external">
          "Screening tests in children and adolescents", section on 'Lead poisoning'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Symptomatic patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         The symptoms of lead toxicity by level of exposure are shown in the table  (
         <a class="graphic graphic_table graphicRef76585" href="/z/d/graphic/76585.html" rel="external">
          table 3
         </a>
         ). They include cognitive impairment, language delay, and behavior problems at low concentrations and progress to vomiting, colicky abdominal pain, fatigue, renal insufficiency, and encephalopathy at higher concentrations. Lead poisoning should be included in the differential diagnosis for children with any of these complaints or conditions [
         <a href="#rid118">
          118
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Encephalopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         When a patient presents with an acute onset of persistent vomiting, alteration of mental status, and/or seizures consistent with lead encephalopathy and a BLL cannot be obtained emergently, one or more of the following clinical findings constitute strong supportive evidence for a diagnosis of lead poisoning and permit emergency initiation of chelation therapy pending confirmation by blood lead testing [
         <a href="#rid119">
          119,120
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age one to five years
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prodrome of gastrointestinal symptoms with progression from lethargy to encephalopathy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of pica, prior increased lead levels, or other history of lead exposure
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Strongly positive qualitative urine coproporphyrin
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated erythrocyte protoporphyrin
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basophilic stippling of peripheral red blood cells or erythroblasts in the bone marrow  (
         <a class="graphic graphic_picture graphicRef71989" href="/z/d/graphic/71989.html" rel="external">
          picture 1
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypophosphatemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glycosuria
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lead flecks on abdominal radiograph  (
         <a class="graphic graphic_diagnosticimage graphicRef81950" href="/z/d/graphic/81950.html" rel="external">
          image 1
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lead lines on long-bone radiographs  (
         <a class="graphic graphic_diagnosticimage graphicRef81488" href="/z/d/graphic/81488.html" rel="external">
          image 2
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Children with lead encephalopathy almost always have elevated blood erythrocyte protoporphyrin (EP) or zinc protoporphyrin (ZPP) concentrations (&gt;35 mcg/dL) [
         <a href="#rid121">
          121
         </a>
         ]. Both are precursors of heme and become elevated as lead inhibits heme synthesis [
         <a href="#rid122">
          122
         </a>
         ]. Thus, elevated EP or ZPP concentrations can be used as a rapid confirmatory test in most hospitals. However, it should be noted that elevated ZPP is usually not seen until the BLL is above 30 mcg/dL and may not be elevated in acute exposures given the delay from lead's effect on heme synthesis. (See
         <a class="local">
          'Erythrocyte protoporphyrin'
         </a>
         below.)
        </p>
        <p>
         Emergency treatment should begin if encephalopathy secondary to severe lead toxicity is suspected. A BLL should be obtained to confirm the diagnosis, but treatment should
         <strong>
          not
         </strong>
         be delayed while awaiting the result. (See
         <a class="medical medical_review" href="/z/d/html/6494.html" rel="external">
          "Childhood lead poisoning: Management", section on 'Symptomatic lead poisoning'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          History
         </span>
         <span class="headingEndMark">
          —
         </span>
         A careful history should be obtained from the families of all children suspected of toxic lead exposure  (
         <a class="graphic graphic_table graphicRef58514" href="/z/d/graphic/58514.html" rel="external">
          table 4
         </a>
         ). The history should include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Onset and severity of symptoms of toxicity  (
         <a class="graphic graphic_table graphicRef76585" href="/z/d/graphic/76585.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nutritional history with particular attention to intake of iron and calcium
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of pica
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Family history of lead poisoning
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Foreign birthplace and recent foreign residence with attention to refugee status [
         <a href="#rid123">
          123-126
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment of potential sources of lead exposure: work history of the parents/primary caregivers and other significant caregivers, hobbies, age of the home and history of home renovations, source of water supply, location and condition of play areas, use of imported or glazed ceramics, imported jewelry and cosmetics, and proximity to industrial facilities or hazardous waste sites  (
         <a class="graphic graphic_table graphicRef53953" href="/z/d/graphic/53953.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are few specific findings on physical examination that can help identify the presence of lead poisoning:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Delayed language development and neurobehavioral dysfunction are important features and should raise concern for lead poisoning when present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lethargy is particularly concerning because it indicates encephalopathy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lead lines, at the junction of the teeth and gums, are rarely seen. If present, they usually indicate severe and prolonged lead exposure  (
         <a class="graphic graphic_picture graphicRef77682" href="/z/d/graphic/77682.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Laboratory evaluation
         </span>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h3">
          Lead levels
         </span>
         <span class="headingEndMark">
          —
         </span>
         The laboratory evaluation of the child with lead poisoning should include a repeat venous blood lead level (BLL) to confirm the diagnosis. BLLs should also be obtained in the patient's siblings, housemates, and/or playmates. Parents/primary caregivers may also require testing, especially if the child is an infant who is not crawling or is breastfeeding. All family members should be tested if the source is not found to be from peeling paint chips or soil because household items (eg, cosmetics, jewelry, pottery, or spices) are shared by everyone in the home. Confirmatory samples should be obtained through venous sampling and processed in lead-free collection tubes. The phlebotomy site should be carefully cleaned with an alcohol wipe to remove any lead from the skin surface.
        </p>
        <p>
         Capillary blood sampling is simpler than venous blood sampling for lead screening and is a valid collection method if it is performed properly [
         <a href="#rid127">
          127
         </a>
         ]. However, capillary samples are subject to contamination with exogenous lead and can yield false-positive results. Common causes of falsely elevated BLLs from capillary lead sampling include [
         <a href="#rid128">
          128
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inadequate use of gloves by phlebotomists
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of alcohol wipes contaminated with lead-based ink
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inadequate cleansing of the child's finger
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Failure to wipe off the first drop of blood
        </p>
        <p>
        </p>
        <p>
         The limit of detection of point-of-care tests are such that lead levels below 5 mcg/dL (0.24 micromol/L) may not be accurate [
         <a href="#rid129">
          129
         </a>
         ]. Despite the reference level set by the Centers for Disease Control and Prevention (CDC; 3.5 mcg/dL [0.14 micromol/L]), the response to an elevated BLL should remain the same and is dependent on the resources available to local and state health departments. Despite potential inaccuracy, point-of-care tests are still our preferred method of lead screening because their use is associated with much higher screening rates [
         <a href="#rid130">
          130
         </a>
         ].
        </p>
        <p>
         All patients who have elevated BLLs on capillary samples must have confirmatory venous blood testing. However, an elevated capillary blood lead result may indicate lead in the environment and proceeding with anticipatory guidance for reducing lead risk is appropriate pending confirmation.
        </p>
        <p>
         Federal regulations in the United States permit laboratories that perform BLL testing to operate with an allowable error of ±4 mcg/dL (0.19 micromol/L) or 10 percent, whichever is greater [
         <a href="#rid131">
          131,132
         </a>
         ]. As an example, a laboratory that meets proficiency standards may report an actual BLL of 8 mcg/dL (0.38 micromol/L) as any value ranging from 4 to 12 mcg/dL (0.19 to 0.58 micromol/L).
        </p>
        <p>
         Bone and dentine lead levels, measured by K x-ray fluorescence spectroscopy or atomic absorption spectroscopy, respectively, are better indicators of the child's total lead burden than BLLs [
         <a href="#rid38">
          38,73,90
         </a>
         ]. However, these tests are not routinely available and are not recommended by the CDC [
         <a href="#rid133">
          133
         </a>
         ]. BLLs remain the gold standard for the diagnosis of lead poisoning in children. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h3">
          Erythrocyte protoporphyrin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Erythrocyte protoporphyrin (EP), typically assayed as zinc protoporphyrin (ZPP), is elevated (greater than 35 mcg/dL) in iron deficiency, lead poisoning, many erythrocyte disorders, and porphyria. Thus, it is not diagnostic for lead poisoning. EP levels usually are not elevated until lead levels are greater than 30 mcg/dL (1.45 micromol/L) [
         <a href="#rid10">
          10,134,135
         </a>
         ]. Thus, EP is
         <strong>
          not
         </strong>
         a good screening test for mild lead toxicity and is not recommended for screening for pediatric lead poisoning.
        </p>
        <p>
        </p>
        <ul class="bulletCompact-block">
         <li>
          EP can be helpful to diagnose moderate to severe lead poisoning and determine the acuity of the exposure as follows:
         </li>
        </ul>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An EP ≥250 mcg/dL (4.44 micromol/L) in a patient with findings suggestive of lead encephalopathy supports the initiation of emergency chelation in situations where the results of a venous BLL are not rapidly available [
         <a href="#rid136">
          136-138
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6494.html" rel="external">
          "Childhood lead poisoning: Management", section on 'Symptomatic lead poisoning'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         EP can also help identify the acuity of lead exposure when measured along with a venous BLL. If the BLL is markedly elevated but the EP is normal, then lead exposure is acute [
         <a href="#rid139">
          139
         </a>
         ]. However, if both the BLL and EP are elevated, then the exposure is likely chronic [
         <a href="#rid140">
          140
         </a>
         ]. Thus an EP is suggested for all children with a BLL that warrants chelation (&gt;45 mcg/dL [2.17 micromol/L])  (
         <a class="graphic graphic_table graphicRef107904" href="/z/d/graphic/107904.html" rel="external">
          table 5
         </a>
         ). However, if the results of EP testing are not rapidly available, chelation should proceed based upon the BLL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The pattern of decline in EP in lead poisoned patients who have received chelation provides information regarding the level of body burden of lead. However, there is a delay in the decrease in EP after chelation due to delayed recovery of the heme synthesis pathway when it has been inhibited by elevated lead levels.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h3">
          Additional tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with elevated BLLs, screening for iron deficiency anemia should also occur (eg, complete blood count, ferritin, and C-reactive protein) [
         <a href="#rid133">
          133
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5925.html" rel="external">
          "Iron deficiency in infants and children &lt;12 years: Screening, prevention, clinical manifestations, and diagnosis", section on 'Laboratory screening'
         </a>
         .)
        </p>
        <p>
         Additional tests are necessary for children who require chelation therapy (see
         <a class="medical medical_review" href="/z/d/html/6494.html" rel="external">
          "Childhood lead poisoning: Management", section on 'Initial evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6494.html" rel="external">
          "Childhood lead poisoning: Management", section on 'Pharmacologic agents for chelation'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum electrolytes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blood urea nitrogen and creatinine
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum calcium and magnesium
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alanine and aspartate aminotransferases
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urinalysis
        </p>
        <p>
        </p>
        <p>
         In addition, screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency should be performed in patients who will be treated with
         <a class="drug drug_pediatric" data-topicid="13235" href="/z/d/drug information/13235.html" rel="external">
          dimercaprol
         </a>
         or succimer and who have risk factors or findings consistent with the disease. (See
         <a class="medical medical_review" href="/z/d/html/6494.html" rel="external">
          "Childhood lead poisoning: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">
          "Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Diagnostic imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         A plain abdominal radiograph should be obtained in symptomatic children or those with a history of pica or acute ingestion of lead-containing objects (eg, fishing weights) to identify leaded objects (eg, lead toys, leaded paint chip, or lead flecks in the stool).
        </p>
        <p>
         Radio-opaque lead flecks in the intestinal tract suggesting recent ingestion are found inconsistently  (
         <a class="graphic graphic_diagnosticimage graphicRef81950" href="/z/d/graphic/81950.html" rel="external">
          image 1
         </a>
         ). However, their presence may have implications for treatment at the time of diagnosis [
         <a href="#rid119">
          119
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6494.html" rel="external">
          "Childhood lead poisoning: Management"
         </a>
         .)
        </p>
        <p>
         The CDC does not recommend obtaining long-bone radiographs in the evaluation of children with lead exposure [
         <a href="#rid133">
          133
         </a>
         ]. Lead lines at the end of growing long bones  (
         <a class="graphic graphic_diagnosticimage graphicRef81488" href="/z/d/graphic/81488.html" rel="external">
          image 2
         </a>
         ) are found only in children with BLLs greater than 45 mcg/dL (2.2 micromol/L). Thus, long-bone radiographs are
         <strong>
          not
         </strong>
         useful as part of the diagnostic evaluation of children with lower BLLs and are not used as a diagnostic tool, routinely, in children with lead levels greater than 45 mcg/dL.
        </p>
        <p>
         Computed tomography of the head should be obtained in children with signs of lead encephalopathy to assess for findings of increased intracranial pressure.
        </p>
        <p>
         Magnetic resonance imaging in adults with chronic elevated BLLs has shown decreased myelination and white matter loss [
         <a href="#rid141">
          141
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2111005373">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of childhood lead poisoning is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6494.html" rel="external">
          "Childhood lead poisoning: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3210129239">
         <span class="h1">
          ADDITIONAL RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H3940778317">
         <span class="h2">
          Lead poisoning management resources
         </span>
         <span class="headingEndMark">
          —
         </span>
         To identify a physician and other clinicians with expertise in managing childhood lead poisoning, contact the regional health department, regional poison control center, or, in the United States, a Pediatric Environmental Health Specialty Unit.
        </p>
        <p>
         In the United States, additional sources for information for the general public and professionals include the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fnceh%2Flead%2F&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLKpPivvdc3zGgFgsHJRmLBTyJIdyVqhPErQVlmbGh4vZ&amp;TOPIC_ID=6491" target="_blank">
          Centers for Disease Control and Prevention
         </a>
         (CDC; 1-800-CDC-INFO [800-232-4636]),
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.pehsu.net%2F&amp;token=kgWnuLuwd5ywHVQww%2BY9eh5uYOTFDxvbdAzG54Anewc%3D&amp;TOPIC_ID=6491" target="_blank">
          Pediatric Environmental Health Specialty Units
         </a>
         , and the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.epa.gov%2Flead%2Fforms%2Flead-hotline-national-lead-information-center&amp;token=i%2BIXc%2FXZ4tV98nsTZzdmzWxGbhZ29foif8stPYPqAKns%2BSUBaMKp3%2F9DTbzaJylyLiUBPcyKSsKwWvXikE43M%2FKw1jTePRYInQS3lzvTiw0%3D&amp;TOPIC_ID=6491" target="_blank">
          National Lead Information Center
         </a>
         (1-800-424-LEAD [5323]).
        </p>
        <p class="headingAnchor" id="H3415182142">
         <span class="h2">
          Regional poison control centers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">
          "Society guideline links: Regional poison control centers"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3071909368">
         <span class="h2">
          Society guideline links
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112690.html" rel="external">
          "Society guideline links: Lead and other heavy metal poisoning"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – In children, the most serious symptoms of lead poisoning affect the central nervous system with subtle effects (eg, decreased intelligence quotient [IQ] and cognitive effects) occurring at lower levels and severe effects (eg, seizures, encephalopathy) occurring at higher levels. The majority of children with elevated blood lead concentrations will be asymptomatic from overt clinical manifestations of lead poisoning. If present, symptoms will vary depending upon the acuity of the lead exposure and the age of the exposed individual  (
         <a class="graphic graphic_table graphicRef76585" href="/z/d/graphic/76585.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis and evaluation of lead poisoning depends upon whether or not symptoms of lead poisoning are present:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Symptomatic patients
         </strong>
         – Lead poisoning can cause diverse and nonspecific symptoms such as vomiting, cognitive impairment, language delay, hearing loss, and behavior problems at low concentrations and colicky abdominal pain, anemia, intellectual disability, seizures, renal insufficiency, and encephalopathy at higher concentrations  (
         <a class="graphic graphic_table graphicRef76585" href="/z/d/graphic/76585.html" rel="external">
          table 3
         </a>
         ). Lead poisoning should be included in the differential diagnosis for children with any of these complaints or conditions. (See
         <a class="local">
          'Symptomatic patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Symptomatic lead intoxication is a medical emergency warranting an emergency repeat venous blood lead level (BLL) for confirmation, emergency evaluation, hospitalization, and chelation. The laboratory evaluation for these patients is described separately. (See
         <a class="medical medical_review" href="/z/d/html/6494.html" rel="external">
          "Childhood lead poisoning: Management", section on 'Initial evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         When a patient presents with an acute onset of persistent vomiting, alteration of mental status, and/or seizures consistent with lead encephalopathy and a stat BLL is not available, one or more of the following clinical findings constitutes strong supportive evidence for a diagnosis of lead poisoning and permits emergency initiation of chelation therapy pending confirmation by blood lead testing (see
         <a class="local">
          'Encephalopathy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6494.html" rel="external">
          "Childhood lead poisoning: Management", section on 'Symptomatic lead poisoning'
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Age one to five years
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Prodrome of gastrointestinal symptoms with progression from lethargy to encephalopathy
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         History of pica, prior increased lead levels, or other history of lead exposure
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Strongly positive qualitative urine coproporphyrin
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Elevated erythrocyte or zinc protoporphyrin
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Basophilic stippling of peripheral red blood cells or erythroblasts in the bone marrow  (
         <a class="graphic graphic_picture graphicRef71989" href="/z/d/graphic/71989.html" rel="external">
          picture 1
         </a>
         )
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Hypophosphatemia
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Glycosuria
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Lead flecks on abdominal radiograph  (
         <a class="graphic graphic_diagnosticimage graphicRef81950" href="/z/d/graphic/81950.html" rel="external">
          image 1
         </a>
         )
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Lead lines on long-bone radiographs  (
         <a class="graphic graphic_diagnosticimage graphicRef81488" href="/z/d/graphic/81488.html" rel="external">
          image 2
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Asymptomatic patients
         </strong>
         – The diagnosis of lead poisoning in asymptomatic patients usually is made through measurement of an elevated BLL during routine blood lead screening. False-positive elevation caused by contamination of the fingertip can occur if capillary samples are obtained. (See
         <a class="local">
          'Asymptomatic patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         All patients who have elevated BLLs on capillary samples must have confirmatory venous blood testing that are collected in lead-free tubes. Management decisions should only be based upon venous blood lead results  (
         <a class="graphic graphic_table graphicRef107472" href="/z/d/graphic/107472.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="local">
          'Lead levels'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6494.html" rel="external">
          "Childhood lead poisoning: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The limit of detection of point-of-care tests are such that lead levels below 5 mcg/dL (0.24 micromol/L) may not be accurate. Despite the reference level set by the Centers for Disease Control and Prevention (CDC; 3.5 mcg/dL [0.14 micromol/L]), the response to an elevated BLL should remain the same and is dependent on the resources available to local and state health departments.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation of asymptomatic patients
         </strong>
         – In asymptomatic patients with elevated BLLs, additional evaluation includes (see
         <a class="local">
          'Evaluation'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Careful history  (
         <a class="graphic graphic_table graphicRef58514" href="/z/d/graphic/58514.html" rel="external">
          table 4
         </a>
         ) and physical examination to assess for subtle signs of lead poisoning. (See
         <a class="local">
          'History'
         </a>
         above and
         <a class="local">
          'Physical examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Screening for iron deficiency anemia (eg, complete blood count, ferritin, and C-reactive protein). (See
         <a class="local">
          'Additional tests'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5925.html" rel="external">
          "Iron deficiency in infants and children &lt;12 years: Screening, prevention, clinical manifestations, and diagnosis", section on 'Laboratory screening'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Additional studies for asymptomatic children who require chelation therapy (see
         <a class="local">
          'Additional tests'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6494.html" rel="external">
          "Childhood lead poisoning: Management"
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Serum electrolytes
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Blood urea nitrogen and creatinine
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Serum calcium and magnesium
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Alanine and aspartate aminotransferases
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Urinalysis
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Screening for glucose-5-phosphate dehydrogenase (G6PD) deficiency in patients who will be treated with
         <a class="drug drug_pediatric" data-topicid="13235" href="/z/d/drug information/13235.html" rel="external">
          dimercaprol
         </a>
         or succimer and who have risk factors or findings consistent with the disease (see
         <a class="medical medical_review" href="/z/d/html/6494.html" rel="external">
          "Childhood lead poisoning: Management", section on 'Pharmacologic agents for chelation'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A plain abdominal radiograph should be obtained in asymptomatic children with a history of pica or acute ingestion of lead-containing objects (eg, curtain or fishing weights). (See
         <a class="local">
          'Diagnostic imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1797028902">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
        </p>
        <p>
         The editorial staff at UpToDate acknowledge both Richard L Hurwitz, MD and Dean A Lee, MD, PhD, who contributed to earlier versions of this topic review.
        </p>
        <p>
         The UpToDate editorial staff acknowledges extensive contributions of Donald H Mahoney, Jr, MD to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Childhood lead poisoning working group. Childhood Lead Poisoning, World Health Organization, Geneva, Switzerland, 2010. http://apps.who.int/iris/bitstream/10665/136571/1/9789241500333_eng.pdf?ua=1&amp;ua=1 (Accessed on April 29, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nriagu JO. Saturnine gout among Roman aristocrats. Did lead poisoning contribute to the fall of the Empire? N Engl J Med 1983; 308:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Needleman HL. The removal of lead from gasoline: historical and personal reflections. Environ Res 2000; 84:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernberg S. Lead poisoning in a historical perspective. Am J Ind Med 2000; 38:244.
          </a>
         </li>
         <li class="breakAll">
          Lead poisoning and health. Fact sheet No 379. World Health Organization, August 2015. http://www.who.int/mediacentre/factsheets/fs379/en/ (Accessed on April 29, 2020).
         </li>
         <li class="breakAll">
          Rees N, Fuller R. The Toxic Truth: Children’s Exposure to Lead Pollution Undermines a Generation of Future Potential. 2020. The-Toxic-Truth-Childrens-Exposure-To-Lead-Pollution-UNICEF-Pure-Earth-2020.pdf (pureearth.org) http://www.pureearth.org/wp-content/uploads/2021/04/The-Toxic-Truth-Childrens-Exposure-To-Lead-Pollution-UNICEF-Pure-Earth-2020.pdf (Accessed on July 28, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright RO, Tsaih SW, Schwartz J, et al. Association between iron deficiency and blood lead level in a longitudinal analysis of children followed in an urban primary care clinic. J Pediatr 2003; 142:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwong WT, Friello P, Semba RD. Interactions between iron deficiency and lead poisoning: epidemiology and pathogenesis. Sci Total Environ 2004; 330:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim Y, Park S. Iron deficiency increases blood concentrations of neurotoxic metals in children. Korean J Pediatr 2014; 57:345.
          </a>
         </li>
         <li class="breakAll">
          Agency for Toxic Substances and Disease Registry. Case Studies in Environmental Medicine (CSEM): Lead Toxicity Cover Page. https://www.atsdr.cdc.gov/csem/csem.asp?csem=34&amp;po=0 (Accessed on April 29, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raymond J, Wheeler W, Brown MJ, Centers for Disease Control and Prevention (CDC). Lead screening and prevalence of blood lead levels in children aged 1-2 years--Child Blood Lead Surveillance System, United States, 2002-2010 and National Health and Nutrition Examination Survey, United States, 1999-2010. MMWR Suppl 2014; 63:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Blood lead levels--United States, 1999-2002. MMWR Morb Mortal Wkly Rep 2005; 54:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melman ST, Nimeh JW, Anbar RD. Prevalence of elevated blood lead levels in an inner-city pediatric clinic population. Environ Health Perspect 1998; 106:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Blood lead levels in young children--United States and selected states, 1996-1999. MMWR Morb Mortal Wkly Rep 2000; 49:1133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Update: blood lead levels--United States, 1991-1994. MMWR Morb Mortal Wkly Rep 1997; 46:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keller B, Faciano A, Tsega A, Ehrlich J. Epidemiologic Characteristics of Children with Blood Lead Levels ≥45 μg/dL. J Pediatr 2017; 180:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geltman PL, Brown MJ, Cochran J. Lead poisoning among refugee children resettled in Massachusetts, 1995 to 1999. Pediatrics 2001; 108:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung EK, Webb D, Clampet-Lundquist S, Campbell C. A comparison of elevated blood lead levels among children living in foster care, their siblings, and the general population. Pediatrics 2001; 107:E81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Infant lead poisoning associated with use of tiro, an eye cosmetic from Nigeria--Boston, Massachusetts, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newman N, Jones C, Page E, et al. Investigation of Childhood Lead Poisoning from Parental Take-Home Exposure from an Electronic Scrap Recycling Facility — Ohio, 2012. MMWR Morb Mortal Wkly Rep 2015; 64:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Lead exposure from indoor firing ranges among students on shooting teams--Alaska, 2002-2004. MMWR Morb Mortal Wkly Rep 2005; 54:577.
          </a>
         </li>
         <li class="breakAll">
          Annest JL. Trends in the blood lead levels of the US population. In: Lead Versus Health, Rutter M, Jones RR (Eds), John Wiley and Sons, New York 1983. p.33.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruckart PZ, Jones RL, Courtney JG, et al. Update of the Blood Lead Reference Value - United States, 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1509.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. National Report on Human Exposure to Environmental Chemicals cgroup2_LBXBPB_2011-p.pdf (cdc.gov) https://www.cdc.gov/exposurereport/report/pdf/cgroup2_LBXBPB_2011-p.pdf (Accessed on July 28, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Blood lead levels in children aged 1-5 years - United States, 1999-2010. MMWR Morb Mortal Wkly Rep 2013; 62:245.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Blood lead reference value. https://www.cdc.gov/nceh/lead/data/blood-lead-reference-value.htm (Accessed on November 04, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellinger D, Sloman J, Leviton A, et al. Low-level lead exposure and children's cognitive function in the preschool years. Pediatrics 1991; 87:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Needleman HL, Schell A, Bellinger D, et al. The long-term effects of exposure to low doses of lead in childhood. An 11-year follow-up report. N Engl J Med 1990; 322:83.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Preventing lead poisoning in young children: a statement by the Centers for Disease Control, 1991.
         </li>
         <li class="breakAll">
          National Research Council.  Measuring lead exposure in infants, children and other sensitive populations. 1993. National Academies Press.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander FW, Clayton BE, Delves HT. Mineral and trace-metal balances in children receiving normal and synthetic diets. Q J Med 1974; 43:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ziegler EE, Edwards BB, Jensen RL, et al. Absorption and retention of lead by infants. Pediatr Res 1978; 12:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James HM, Hilburn ME, Blair JA. Effects of meals and meal times on uptake of lead from the gastrointestinal tract in humans. Hum Toxicol 1985; 4:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahaffey KR. Environmental lead toxicity: nutrition as a component of intervention. Environ Health Perspect 1990; 89:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffin TB, Coulston F, Wills H, Russell JC. Biologic effects of airborne particulate lead on continuously exposed rats and rhesus monkeys. Environ Qual Saf Suppl 1975; 2:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabinowitz MB, Wetherill GW, Kopple JD. Kinetic analysis of lead metabolism in healthy humans. J Clin Invest 1976; 58:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffin TB, Coulston F, Wills H, Russell JC. Clinical studies on men continuously exposed to airborne particulate lead. Environ Qual Saf Suppl 1975; 2:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu H, Rabinowitz M, Smith D. Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms. Environ Health Perspect 1998; 106:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barry PS. A comparison of concentrations of lead in human tissues. Br J Ind Med 1975; 32:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lidsky TI, Schneider JS. Lead neurotoxicity in children: basic mechanisms and clinical correlates. Brain 2003; 126:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Modhefer AJ, Bradbury MW, Simons TJ. Observations on the chemical nature of lead in human blood serum. Clin Sci (Lond) 1991; 81:823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson FM. The genetic effects of environmental lead. Mutat Res 1998; 410:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox DA, Campbell ML, Blocker YS. Functional alterations and apoptotic cell death in the retina following developmental or adult lead exposure. Neurotoxicology 1997; 18:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox DA, He L, Poblenz AT, et al. Lead-induced alterations in retinal cGMP phosphodiesterase trigger calcium overload, mitochondrial dysfunction and rod photoreceptor apoptosis. Toxicol Lett 1998; 102-103:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           He L, Poblenz AT, Medrano CJ, Fox DA. Lead and calcium produce rod photoreceptor cell apoptosis by opening the mitochondrial permeability transition pore. J Biol Chem 2000; 275:12175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markovac J, Goldstein GW. Picomolar concentrations of lead stimulate brain protein kinase C. Nature 1988; 334:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnston MV, Goldstein GW. Selective vulnerability of the developing brain to lead. Curr Opin Neurol 1998; 11:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srivastava D, Hurwitz RL, Fox DA. Lead- and calcium-mediated inhibition of bovine rod cGMP phosphodiesterase: interactions with magnesium. Toxicol Appl Pharmacol 1995; 134:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srivastava D, Fox DA, Hurwitz RL. Effects of magnesium on cyclic GMP hydrolysis by the bovine retinal rod cyclic GMP phosphodiesterase. Biochem J 1995; 308 ( Pt 2):653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holtzman D, Hsu JS. Early effects of inorganic lead on immature rat brain mitochondrial respiration. Pediatr Res 1976; 10:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trope I, Lopez-Villegas D, Cecil KM, Lenkinski RE. Exposure to lead appears to selectively alter metabolism of cortical gray matter. Pediatrics 2001; 107:1437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trope I, Lopez-Villegas D, Lenkinski RE. Magnetic resonance imaging and spectroscopy of regional brain structure in a 10-year-old boy with elevated blood lead levels. Pediatrics 1998; 101:E7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper GP, Suszkiw JB, Manalis RS. Heavy metals: effects on synaptic transmission. Neurotoxicology 1984; 5:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zwart R, van Kleef RG, Van Hooft JA, et al. Cellular aspects of persistent neurotoxicants: effects of Pb2+ on neuronal nicotinic acetylcholine receptors. Neurotoxicology 1997; 18:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oortgiesen M, Leinders T, van Kleef RG, Vijverberg HP. Differential neurotoxicological effects of lead on voltage-dependent and receptor-operated ion channels. Neurotoxicology 1993; 14:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sirover MA, Loeb LA. Infidelity of DNA synthesis in vitro: screening for potential metal mutagens or carcinogens. Science 1976; 194:1434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffman DJ, Niyogi SK. Metal mutagens and carcinogens affect RNA synthesis rates in a distinct manner. Science 1977; 198:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobayashi N, Okamoto T. Effects of lead oxide on the induction of lung tumors in Syrian hamsters. J Natl Cancer Inst 1974; 52:1605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasprzak KS, Hoover KL, Poirier LA. Effects of dietary calcium acetate on lead subacetate carcinogenicity in kidneys of male Sprague-Dawley rats. Carcinogenesis 1985; 6:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buzard GS, Kasprzak KS. Possible roles of nitric oxide and redox cell signaling in metal-induced toxicity and carcinogenesis: a review. J Environ Pathol Toxicol Oncol 2000; 19:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koller LD, Kerkvliet NI, Exon JH. Neoplasia induced in male rats fed lead acetate, ethyl urea, and sodium nitrite. Toxicol Pathol 1985; 13:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ZOLLINGER HU. [Renal adenoma and carcinoma produced by lead poisoning in rats, and relations to corresponding neoplastic formations in man]. Virchows Arch Pathol Anat Physiol Klin Med 1953; 323:694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Esch GJ, Kroes R. The induction of renal tumours by feeding basic lead acetate to mice and hamsters. Br J Cancer 1969; 23:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DINGWALL-FORDYCE I, LANE RE. A FOLLOW-UP STUDY OF LEAD WORKERS. Br J Ind Med 1963; 20:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore MR, Meredith PA. The carcinogenicity of lead. Arch Toxicol 1979; 42:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson DJ, Kiremidjian-Schumacher L, Stotzky G. Effects of cadmium, lead, and zinc on macrophage-mediated cytotoxicity toward tumor cells. Environ Res 1982; 28:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson DR, Foulkes EC, Hammond PB. The renal handling of delta-aminolevulinic acid in normal and lead-poisoning rabbits. Toxicol Appl Pharmacol 1976; 38:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hammond PB. Exposure of humans to lead. Annu Rev Pharmacol Toxicol 1977; 17:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell BC, Brodie MJ, Thompson GG, et al. Alterations in the activity of enzymes of haem biosynthesis in lead poisoning and acute hepatic prophyria. Clin Sci Mol Med 1977; 53:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Astrin KH, Bishop DF, Wetmur JG, et al. delta-Aminolevulinic acid dehydratase isozymes and lead toxicity. Ann N Y Acad Sci 1987; 514:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rees DC, Duley JA, Marinaki AM. Pyrimidine 5' nucleotidase deficiency. Br J Haematol 2003; 120:375.
          </a>
         </li>
         <li class="breakAll">
          Weitzman ML, Matte T., Homa D, et al. A Review of Evidence of Adverse Health Effects Associated with Blood Lead Levels &lt;10 µg/dL in Children. Reported by Work Group of the Advisory Committee on Childhood Lead Poisoning Prevention to Centers for Disease Control and Prevention, in Preventing Lead Poisoning in Young Children, A statement by the Centers for Disease Control and Prevention, Atlanta, GA August 2005. http://www.cdc.gov/nceh/lead/ACCLPP/meetingMinutes/lessThan10MtgMAR04.pdf (Accessed on April 29, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Needleman HL, Riess JA, Tobin MJ, et al. Bone lead levels and delinquent behavior. JAMA 1996; 275:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendelsohn AL, Dreyer BP, Fierman AH, et al. Low-level lead exposure and behavior in early childhood. Pediatrics 1998; 101:E10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dietrich KN, Krafft KM, Bornschein RL, et al. Low-level fetal lead exposure effect on neurobehavioral development in early infancy. Pediatrics 1987; 80:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dietrich KN, Berger OG, Succop PA, et al. The developmental consequences of low to moderate prenatal and postnatal lead exposure: intellectual attainment in the Cincinnati Lead Study Cohort following school entry. Neurotoxicol Teratol 1993; 15:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baghurst PA, McMichael AJ, Wigg NR, et al. Environmental exposure to lead and children's intelligence at the age of seven years. The Port Pirie Cohort Study. N Engl J Med 1992; 327:1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendelsohn AL, Dreyer BP, Fierman AH, et al. Low-level lead exposure and cognitive development in early childhood. J Dev Behav Pediatr 1999; 20:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pocock SJ, Smith M, Baghurst P. Environmental lead and children's intelligence: a systematic review of the epidemiological evidence. BMJ 1994; 309:1189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen A, Cai B, Dietrich KN, et al. Lead exposure, IQ, and behavior in urban 5- to 7-year-olds: does lead affect behavior only by lowering IQ? Pediatrics 2007; 119:e650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu J, Liu X, Wang W, et al. Blood lead concentrations and children's behavioral and emotional problems: a cohort study. JAMA Pediatr 2014; 168:737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanphear BP, Dietrich K, Auinger P, Cox C. Cognitive deficits associated with blood lead concentrations &lt;10 microg/dL in US children and adolescents. Public Health Rep 2000; 115:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canfield RL, Henderson CR Jr, Cory-Slechta DA, et al. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. N Engl J Med 2003; 348:1517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanphear BP, Hornung R, Khoury J, et al. Low-level environmental lead exposure and children's intellectual function: an international pooled analysis. Environ Health Perspect 2005; 113:894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Téllez-Rojo MM, Bellinger DC, Arroyo-Quiroz C, et al. Longitudinal associations between blood lead concentrations lower than 10 microg/dL and neurobehavioral development in environmentally exposed children in Mexico City. Pediatrics 2006; 118:e323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ji Y, Hong X, Wang G, et al. A Prospective Birth Cohort Study on Early Childhood Lead Levels and Attention Deficit Hyperactivity Disorder: New Insight on Sex Differences. J Pediatr 2018; 199:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White RF, Diamond R, Proctor S, et al. Residual cognitive deficits 50 years after lead poisoning during childhood. Br J Ind Med 1993; 50:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gomaa A, Hu H, Bellinger D, et al. Maternal bone lead as an independent risk factor for fetal neurotoxicity: a prospective study. Pediatrics 2002; 110:110.
          </a>
         </li>
         <li class="breakAll">
          CDC response to Advisory Committee on Childhood Lead Poisoning Prevention Recommendations in "Low Level Lead Exposure Harms Children:  A Renewed Call of Primary Prevention" http://www.cdc.gov/nceh/lead/ACCLPP/activities.htm (Accessed on April 29, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fergusson DM, Horwood LJ, Lynskey MT. Early dentine lead levels and educational outcomes at 18 years. J Child Psychol Psychiatry 1997; 38:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finkelstein Y, Markowitz ME, Rosen JF. Low-level lead-induced neurotoxicity in children: an update on central nervous system effects. Brain Res Brain Res Rev 1998; 27:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellinger D, Leviton A, Waternaux C, et al. Longitudinal analyses of prenatal and postnatal lead exposure and early cognitive development. N Engl J Med 1987; 316:1037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schroeder SR, Hawk B, Otto DA, et al. Separating the effects of lead and social factors on IQ. Environ Res 1985; 38:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruff HA, Bijur PE, Markowitz M, et al. Declining blood lead levels and cognitive changes in moderately lead-poisoned children. JAMA 1993; 269:1641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soong WT, Chao KY, Jang CS, Wang JD. Long-term effect of increased lead absorption on intelligence of children. Arch Environ Health 1999; 54:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellinger DC, Stiles KM, Needleman HL. Low-level lead exposure, intelligence and academic achievement: a long-term follow-up study. Pediatrics 1992; 90:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reuben A, Caspi A, Belsky DW, et al. Association of Childhood Blood Lead Levels With Cognitive Function and Socioeconomic Status at Age 38 Years and With IQ Change and Socioeconomic Mobility Between Childhood and Adulthood. JAMA 2017; 317:1244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellinger DC. Childhood Lead Exposure and Adult Outcomes. JAMA 2017; 317:1219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Searle AK, Baghurst PA, van Hooff M, et al. Tracing the long-term legacy of childhood lead exposure: a review of three decades of the port Pirie cohort study. Neurotoxicology 2014; 43:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koller K, Brown T, Spurgeon A, Levy L. Recent developments in low-level lead exposure and intellectual impairment in children. Environ Health Perspect 2004; 112:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruff HA. Population-based data and the development of individual children: the case of low to moderate lead levels and intelligence. J Dev Behav Pediatr 1999; 20:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suarez CR, Black LE 3rd, Hurley RM. Elevated lead levels in a patient with sickle cell disease and inappropriate secretion of antidiuretic hormone. Pediatr Emerg Care 1992; 8:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MYERSON RM, EISENHAUER JH. Atrioventricular conduction defects in lead poisoning. Am J Cardiol 1963; 11:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osman K, Pawlas K, Schütz A, et al. Lead exposure and hearing effects in children in Katowice, Poland. Environ Res 1999; 80:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CHISOLM JJ Jr, HARRISON HE. The exposure of children to lead. Pediatrics 1956; 18:943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erenberg G, Rinsler SS, Fish BG. Lead neuropathy and sickle cell disease. Pediatrics 1974; 54:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anku VD, Harris JW. Peripheral neuropathy and lead poisoning in a child with sickle-cell anemia. Case report and review of the literature. J Pediatr 1974; 85:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imbus CE, Warner J, Smith E, et al. Peripheral neuropathy in lead-intoxicated sickle cell patients. Muscle Nerve 1978; 1:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feldman RG, Hayes MK, Younes R, Aldrich FD. Lead neuropathy in adults and children. Arch Neurol 1977; 34:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz J, Landrigan PJ, Feldman RG, et al. Threshold effect in lead-induced peripheral neuropathy. J Pediatr 1988; 112:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loghman-Adham M. Aminoaciduria and glycosuria following severe childhood lead poisoning. Pediatr Nephrol 1998; 12:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen JF, Chesney RW, Hamstra A, et al. Reduction in 1,25-dihydroxyvitamin D in children with increased lead absorption. N Engl J Med 1980; 302:1128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lubran MM. Lead toxicity and heme biosynthesis. Ann Clin Lab Sci 1980; 10:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meredith PA, Moore MR, Goldberg A. Erythrocyte delta-aminolaevulinic acid dehydratase activity and blood protoporphyrin concentrations as indices of lead exposure and altered haem biosynthesis. Clin Sci (Lond) 1979; 56:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hammad TA, Sexton M, Langenberg P. Relationship between blood lead and dietary iron intake in preschool children. A cross-sectional study. Ann Epidemiol 1996; 6:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark M, Royal J, Seeler R. Interaction of iron deficiency and lead and the hematologic findings in children with severe lead poisoning. Pediatrics 1988; 81:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhambhani K, Aronow R. Lead poisoning and thalassemia trait or iron deficiency. The value of the red blood cell distribution width. Am J Dis Child 1990; 144:1231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewendon G, Kinra S, Nelder R, Cronin T. Should children with developmental and behavioural problems be routinely screened for lead? Arch Dis Child 2001; 85:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon RA, Roberts G, Amin Z, et al. Aggressive approach in the treatment of acute lead encephalopathy with an extraordinarily high concentration of lead. Arch Pediatr Adolesc Med 1998; 152:1100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chisolm JJ Jr. The use of chelating agents in the treatment of acute and chronic lead intoxication in childhood. J Pediatr 1968; 73:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chisolm JJ Jr. The continuing hazard of lead exposure and its effects in children. Neurotoxicology 1984; 5:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soldin OP, Pezzullo JC, Hanak B, et al. Changing trends in the epidemiology of pediatric lead exposure: interrelationship of blood lead and ZPP concentrations and a comparison to the US population. Ther Drug Monit 2003; 25:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tehranifar P, Leighton J, Auchincloss AH, et al. Immigration and risk of childhood lead poisoning: findings from a case control study of New York City children. Am J Public Health 2008; 98:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geltman PL, Smock L, Cochran J. Trends in Elevated Blood Lead Levels Using 5 and 10 µg/dL Levels of Concern Among Refugee Children Resettled in Massachusetts, 1998-2015. Public Health Rep 2019; 134:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shakya S, Bhatta MP. Elevated Blood Lead Levels Among Resettled Refugee Children in Ohio, 2009-2016. Am J Public Health 2019; 109:912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pezzi C, Lee D, Kennedy L, et al. Blood Lead Levels Among Resettled Refugee Children in Select US States, 2010-2014. Pediatrics 2019; 143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parsons PJ, Reilly AA, Esernio-Jenssen D. Screening children exposed to lead: an assessment of the capillary blood lead fingerstick test. Clin Chem 1997; 43:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Screening for elevated blood lead levels. American Academy of Pediatrics Committee on Environmental Health. Pediatrics 1998; 101:1072.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakata H, Nakayama SMM, Yabe J, et al. Assessment of LeadCare® II analysis for testing of a wide range of blood lead levels in comparison with ICP-MS analysis. Chemosphere 2021; 271:129832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carnahan B, Schaefer EW, Fogel BN. Point-of-Care Testing Improves Lead Screening Rates at 1- and 2-Year Well Visits. J Pediatr 2021; 233:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Binns HJ, Campbell C, Brown MJ, Centers for Disease Control and Prevention Advisory Committee on Childhood Lead Poisoning Prevention. Interpreting and managing blood lead levels of less than 10 microg/dL in children and reducing childhood exposure to lead: recommendations of the Centers for Disease Control and Prevention Advisory Committee on Childhood Lead Poisoning Prevention. Pediatrics 2007; 120:e1285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caldwell KL, Cheng PY, Jarrett JM, et al. Measurement Challenges at Low Blood Lead Levels. Pediatrics 2017; 140.
          </a>
         </li>
         <li class="breakAll">
          Roberts, JR, Reigart, JR. Medical Assessment and Interventions. In: Managing Elevated Blood Lead Levels Among Young children: Recommendations from the Advisory Committee on Childhood Lead Poisoning Prevention. Centers for Disease Control and Prevention, Atlanta, GA, 2002.
         </li>
         <li>
          <a class="nounderline abstract_t">
           McElvaine MD, Orbach HG, Binder S, et al. Evaluation of the erythrocyte protoporphyrin test as a screen for elevated blood lead levels. J Pediatr 1991; 119:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porru S, Alessio L. The use of chelating agents in occupational lead poisoning. Occup Med (Lond) 1996; 46:41.
          </a>
         </li>
         <li class="breakAll">
          Calello DP, Henretig FM. Lead. In: Goldfrank's Toxicologic Emergencies, 10th ed, Hoffman RS, Howland MA, Lewin NA, et al (Eds), McGraw Hill Education, New York 2015. p.1219.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaltout AA, Ghawaby MM, Hassan MF, et al. High incidence of lead poisoning revealed by erythrocyte protoporphyrin (EPP) screening in Arabian children. Ann Trop Paediatr 1985; 5:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selbst SM, Henretig FM, Pearce J. Lead encephalopathy. A case report and review of management. Clin Pediatr (Phila) 1985; 24:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones A. Emerging aspects of assessing lead poisoning in childhood. Emerg Health Threats J 2009; 2:e3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin CJ, Werntz CL 3rd, Ducatman AM. The interpretation of zinc protoporphyrin changes in lead intoxication: a case report and review of the literature. Occup Med (Lond) 2004; 54:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz BS, Caffo B, Stewart WF, et al. Evaluation of cumulative lead dose and longitudinal changes in structural magnetic resonance imaging in former organolead workers. J Occup Environ Med 2010; 52:407.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6491 Version 38.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="http://apps.who.int/iris/bitstream/10665/136571/1/9789241500333_eng.pdf?ua=1&amp;ua=1" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Childhood lead poisoning working group. Childhood Lead Poisoning, World Health Organization, Geneva, Switzerland, 2010. http://apps.who.int/iris/bitstream/10665/136571/1/9789241500333_eng.pdf?ua=1&amp;ua=1 (Accessed on April 29, 2020).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6338384" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Saturnine gout among Roman aristocrats. Did lead poisoning contribute to the fall of the Empire?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10991779" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The removal of lead from gasoline: historical and personal reflections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10940962" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Lead poisoning in a historical perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10940962" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Lead poisoning in a historical perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10940962" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Lead poisoning in a historical perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12520247" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Association between iron deficiency and blood lead level in a longitudinal analysis of children followed in an urban primary care clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15325155" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Interactions between iron deficiency and lead poisoning: epidemiology and pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25210521" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Iron deficiency increases blood concentrations of neurotoxic metals in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25210521" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Iron deficiency increases blood concentrations of neurotoxic metals in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25208256" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Lead screening and prevalence of blood lead levels in children aged 1-2 years--Child Blood Lead Surveillance System, United States, 2002-2010 and National Health and Nutrition Examination Survey, United States, 1999-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15917736" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Blood lead levels--United States, 1999-2002.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9755141" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prevalence of elevated blood lead levels in an inner-city pediatric clinic population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11190117" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Blood lead levels in young children--United States and selected states, 1996-1999.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9072671" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Update: blood lead levels--United States, 1991-1994.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27771006" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Epidemiologic Characteristics of Children with Blood Lead Levels≥45 μg/dL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11433069" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Lead poisoning among refugee children resettled in Massachusetts, 1995 to 1999.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11331731" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A comparison of elevated blood lead levels among children living in foster care, their siblings, and the general population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22854626" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Infant lead poisoning associated with use of tiro, an eye cosmetic from Nigeria--Boston, Massachusetts, 2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26182192" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Investigation of Childhood Lead Poisoning from Parental Take-Home Exposure from an Electronic Scrap Recycling Facility—Ohio, 2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15959452" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Lead exposure from indoor firing ranges among students on shooting teams--Alaska, 2002-2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15959452" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Lead exposure from indoor firing ranges among students on shooting teams--Alaska, 2002-2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34710078" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Update of the Blood Lead Reference Value - United States, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34710078" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Update of the Blood Lead Reference Value - United States, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23552225" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Blood lead levels in children aged 1-5 years - United States, 1999-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23552225" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Blood lead levels in children aged 1-5 years - United States, 1999-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1987535" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Low-level lead exposure and children's cognitive function in the preschool years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2294437" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The long-term effects of exposure to low doses of lead in childhood. An 11-year follow-up report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2294437" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The long-term effects of exposure to low doses of lead in childhood. An 11-year follow-up report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2294437" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The long-term effects of exposure to low doses of lead in childhood. An 11-year follow-up report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4822973" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Mineral and trace-metal balances in children receiving normal and synthetic diets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/643372" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Absorption and retention of lead by infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4018820" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Effects of meals and meal times on uptake of lead from the gastrointestinal tract in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2088758" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Environmental lead toxicity: nutrition as a component of intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1058105" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Biologic effects of airborne particulate lead on continuously exposed rats and rhesus monkeys.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/783195" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Kinetic analysis of lead metabolism in healthy humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1058106" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Clinical studies on men continuously exposed to airborne particulate lead.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9417769" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1131339" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A comparison of concentrations of lead in human tissues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12477693" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Lead neurotoxicity in children: basic mechanisms and clinical correlates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1662590" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Observations on the chemical nature of lead in human blood serum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9637233" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The genetic effects of environmental lead.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9339814" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Functional alterations and apoptotic cell death in the retina following developmental or adult lead exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10022279" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Lead-induced alterations in retinal cGMP phosphodiesterase trigger calcium overload, mitochondrial dysfunction and rod photoreceptor apoptosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10766853" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Lead and calcium produce rod photoreceptor cell apoptosis by opening the mitochondrial permeability transition pore.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3386747" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Picomolar concentrations of lead stimulate brain protein kinase C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9870138" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Selective vulnerability of the developing brain to lead.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7676457" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Lead- and calcium-mediated inhibition of bovine rod cGMP phosphodiesterase: interactions with magnesium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7772055" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Effects of magnesium on cyclic GMP hydrolysis by the bovine retinal rod cyclic GMP phosphodiesterase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/174053" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Early effects of inorganic lead on immature rat brain mitochondrial respiration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11389272" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Exposure to lead appears to selectively alter metabolism of cortical gray matter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9606249" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Magnetic resonance imaging and spectroscopy of regional brain structure in a 10-year-old boy with elevated blood lead levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6097846" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Heavy metals: effects on synaptic transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9339818" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Cellular aspects of persistent neurotoxicants: effects of Pb2+ on neuronal nicotinic acetylcholine receptors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7504228" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Differential neurotoxicological effects of lead on voltage-dependent and receptor-operated ion channels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1006310" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Infidelity of DNA synthesis in vitro: screening for potential metal mutagens or carcinogens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/910143" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Metal mutagens and carcinogens affect RNA synthesis rates in a distinct manner.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4831445" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Effects of lead oxide on the induction of lung tumors in Syrian hamsters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3971492" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Effects of dietary calcium acetate on lead subacetate carcinogenicity in kidneys of male Sprague-Dawley rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10983886" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Possible roles of nitric oxide and redox cell signaling in metal-induced toxicity and carcinogenesis: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4035262" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Neoplasia induced in male rats fed lead acetate, ethyl urea, and sodium nitrite.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13102931" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : [Renal adenoma and carcinoma produced by lead poisoning in rats, and relations to corresponding neoplastic formations in man].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5367336" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The induction of renal tumours by feeding basic lead acetate to mice and hamsters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14072623" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : A FOLLOW-UP STUDY OF LEAD WORKERS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/384969" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : The carcinogenicity of lead.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7106071" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Effects of cadmium, lead, and zinc on macrophage-mediated cytotoxicity toward tumor cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/982461" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : The renal handling of delta-aminolevulinic acid in normal and lead-poisoning rabbits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/326164" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Exposure of humans to lead.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/913057" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Alterations in the activity of enzymes of haem biosynthesis in lead poisoning and acute hepatic prophyria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3442386" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : delta-Aminolevulinic acid dehydratase isozymes and lead toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12580951" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Pyrimidine 5' nucleotidase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12580951" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Pyrimidine 5' nucleotidase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8569015" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Bone lead levels and delinquent behavior.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9481029" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Low-level lead exposure and behavior in early childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2444921" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Low-level fetal lead exposure effect on neurobehavioral development in early infancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8459787" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : The developmental consequences of low to moderate prenatal and postnatal lead exposure: intellectual attainment in the Cincinnati Lead Study Cohort following school entry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1383818" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Environmental exposure to lead and children's intelligence at the age of seven years. The Port Pirie Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10608372" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Low-level lead exposure and cognitive development in early childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7987149" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Environmental lead and children's intelligence: a systematic review of the epidemiological evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17332184" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Lead exposure, IQ, and behavior in urban 5- to 7-year-olds: does lead affect behavior only by lowering IQ?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25090293" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Blood lead concentrations and children's behavioral and emotional problems: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11354334" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Cognitive deficits associated with blood lead concentrations&lt;10 microg/dL in US children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12700371" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16002379" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Low-level environmental lead exposure and children's intellectual function: an international pooled analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16882776" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Longitudinal associations between blood lead concentrations lower than 10 microg/dL and neurobehavioral development in environmentally exposed children in Mexico City.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29752174" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : A Prospective Birth Cohort Study on Early Childhood Lead Levels and Attention Deficit Hyperactivity Disorder: New Insight on Sex Differences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8343422" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Residual cognitive deficits 50 years after lead poisoning during childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12093955" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Maternal bone lead as an independent risk factor for fetal neurotoxicity: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12093955" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Maternal bone lead as an independent risk factor for fetal neurotoxicity: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9232492" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Early dentine lead levels and educational outcomes at 18 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9622620" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Low-level lead-induced neurotoxicity in children: an update on central nervous system effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3561456" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Longitudinal analyses of prenatal and postnatal lead exposure and early cognitive development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4076103" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Separating the effects of lead and social factors on IQ.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8455297" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Declining blood lead levels and cognitive changes in moderately lead-poisoned children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10433190" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Long-term effect of increased lead absorption on intelligence of children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1437425" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Low-level lead exposure, intelligence and academic achievement: a long-term follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28350927" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Association of Childhood Blood Lead Levels With Cognitive Function and Socioeconomic Status at Age 38 Years and With IQ Change and Socioeconomic Mobility Between Childhood and Adulthood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28350907" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Childhood Lead Exposure and Adult Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24785378" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Tracing the long-term legacy of childhood lead exposure: a review of three decades of the port Pirie cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15198918" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Recent developments in low-level lead exposure and intellectual impairment in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10071946" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Population-based data and the development of individual children: the case of low to moderate lead levels and intelligence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1603708" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Elevated lead levels in a patient with sickle cell disease and inappropriate secretion of antidiuretic hormone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13936981" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Atrioventricular conduction defects in lead poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9931221" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Lead exposure and hearing effects in children in Katowice, Poland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13378923" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : The exposure of children to lead.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4370143" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Lead neuropathy and sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4372553" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Peripheral neuropathy and lead poisoning in a child with sickle-cell anemia. Case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/220532" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Peripheral neuropathy in lead-intoxicated sickle cell patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/889480" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Lead neuropathy in adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2826742" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Threshold effect in lead-induced peripheral neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9630041" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Aminoaciduria and glycosuria following severe childhood lead poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7366636" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Reduction in 1,25-dihydroxyvitamin D in children with increased lead absorption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6999974" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Lead toxicity and heme biosynthesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/477184" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Erythrocyte delta-aminolaevulinic acid dehydratase activity and blood protoporphyrin concentrations as indices of lead exposure and altered haem biosynthesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8680621" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Relationship between blood lead and dietary iron intake in preschool children. A cross-sectional study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3277157" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Interaction of iron deficiency and lead and the hematologic findings in children with severe lead poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2239862" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Lead poisoning and thalassemia trait or iron deficiency. The value of the red blood cell distribution width.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11567935" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Should children with developmental and behavioural problems be routinely screened for lead?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9811288" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Aggressive approach in the treatment of acute lead encephalopathy with an extraordinarily high concentration of lead.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4969284" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : The use of chelating agents in the treatment of acute and chronic lead intoxication in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6542978" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : The continuing hazard of lead exposure and its effects in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12883223" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Changing trends in the epidemiology of pediatric lead exposure: interrelationship of blood lead and ZPP concentrations and a comparison to the US population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18048801" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Immigration and risk of childhood lead poisoning: findings from a case control study of New York City children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31539488" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Trends in Elevated Blood Lead Levels Using 5 and 10µg/dL Levels of Concern Among Refugee Children Resettled in Massachusetts, 1998-2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30998405" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Elevated Blood Lead Levels Among Resettled Refugee Children in Ohio, 2009-2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30996119" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Blood Lead Levels Among Resettled Refugee Children in Select US States, 2010-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9023133" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Screening children exposed to lead: an assessment of the capillary blood lead fingerstick test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9614424" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Screening for elevated blood lead levels. American Academy of Pediatrics Committee on Environmental Health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33736222" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Assessment of LeadCare®II analysis for testing of a wide range of blood lead levels in comparison with ICP-MS analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33675816" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Point-of-Care Testing Improves Lead Screening Rates at 1- and 2-Year Well Visits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17974722" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Interpreting and managing blood lead levels of less than 10 microg/dL in children and reducing childhood exposure to lead: recommendations of the Centers for Disease Control and Prevention Advisory Committee on Childhood Lead Poisoning Prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28771411" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Measurement Challenges at Low Blood Lead Levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28771411" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Measurement Challenges at Low Blood Lead Levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1919884" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Evaluation of the erythrocyte protoporphyrin test as a screen for elevated blood lead levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8672793" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : The use of chelating agents in occupational lead poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8672793" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : The use of chelating agents in occupational lead poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2418770" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : High incidence of lead poisoning revealed by erythrocyte protoporphyrin (EPP) screening in Arabian children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3987168" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Lead encephalopathy. A case report and review of management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22460284" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Emerging aspects of assessing lead poisoning in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15576877" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : The interpretation of zinc protoporphyrin changes in lead intoxication: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20357679" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Evaluation of cumulative lead dose and longitudinal changes in structural magnetic resonance imaging in former organolead workers.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
